5637 Xenograft Model Service for Bladder Cancer

The 5637 Xenograft Model Service for Bladder Cancer provides a robust, translationally relevant platform for evaluating novel therapeutic candidates against urothelial carcinoma. At Alfa Cytology, we specialize in constructing high-fidelity preclinical tumor models, and our 5637 xenograft program is meticulously designed to accelerate your bladder cancer drug development pipeline with reproducible, pharmacologically predictive data.

Overview of 5637 Xenograft Model for Bladder Cancer

The 5637 cell line, originally derived in 1974 from a Grade II transitional cell carcinoma of the bladder in a 68-year-old male patient, represents one of the most extensively characterized human bladder cancer models in oncology research. As an epithelial cell line with classic cobblestone morphology, 5637 robustly expresses urothelial differentiation markers including cytokeratins and maintains an aneuploid karyotype characteristic of urothelial tumors. In xenograft settings, 5637 cells reliably form subcutaneous tumors in immunocompromised murine hosts, offering investigators a consistent, scalable platform to study tumor growth dynamics, angiogenesis, and therapeutic response in an in vivo microenvironment that recapitulates key features of human bladder cancer.

Beyond its foundational role in bladder cancer biology, the 5637 xenograft model has been instrumental in preclinical evaluation of chemotherapeutic agents, targeted inhibitors, and immunotherapeutic strategies. The model's documented responsiveness to cisplatin-based regimens and its utility in dissecting molecular subtype plasticity---particularly luminal-to-basal transitions---make it an indispensable tool for translational studies. At Alfa Cytology, we leverage this well-established model to support pharmacokinetic-pharmacodynamic (PK-PD) analyses, combination therapy screening, and biomarker discovery programs, ensuring that your preclinical data package meets the rigorous standards required for IND-enabling studies.

Figure 1. The effects of Tet-inducible artificial microRNAs on cell migration in bladder cancer cells. (Zhan, Y, et al., 2023)

Cell Line Information: 5637

The following table summarizes the comprehensive characteristics of the 5637 cell line essential for preclinical xenograft study design and interpretation:

Our Services

Alfa Cytology delivers end-to-end preclinical oncology services built on rigorous quality control and scientific excellence. Our 5637 xenograft model program integrates comprehensive cell line authentication, pathogen screening, and standardized tumor monitoring protocols to ensure data integrity and regulatory compliance. Whether you require single-agent efficacy studies, combination therapy assessments, or mechanistic biomarker investigations, our experienced team provides customized study designs, real-time data reporting, and expert interpretation to advance your bladder cancer therapeutic candidates from bench to bedside with confidence and precision.

Workflow of 5637 Xenograft Model Construction

Alfa Cytology follows a standardized, GLP-aligned workflow for 5637 xenograft construction that ensures reproducible tumor growth, ethical compliance, and pharmacological relevance. Each study is initiated with authenticated, low-passage 5637 cells and proceeds through systematic inoculation, monitoring, and endpoint analysis phases to deliver robust, publication-ready datasets.

1. Cell Preparation & Quality Control: 5637 cells are expanded from authenticated master stocks under sterile, low-passage conditions. Prior to inoculation, cells undergo comprehensive pathogen screening (mycoplasma, bacteria, fungi) and viability assessment to confirm >95% viability and optimal growth potential.
2. Mouse Model Selection & Acclimation: Appropriate immunocompromised strains (e.g., BALB/c nude or NOD-SCID) are selected based on study objectives and acclimated for 5-7 days. Health status is verified by veterinary assessment prior to tumor cell inoculation.
3. Subcutaneous Tumor Cell Inoculation: 5637 cells are harvested at logarithmic growth phase, washed, and resuspended in serum-free medium mixed with Matrigel or PBS at defined concentrations (typically 1x10^6 to 5x10^6 cells per 100-200 uL). The cell suspension is injected subcutaneously into the flank region using aseptic technique.
4. Tumor Establishment Monitoring: Mice are monitored daily for general health and twice weekly for tumor palpation. Once tumors become palpable, digital caliper measurements are recorded 2-3 times per week to track growth kinetics. Tumor volume is calculated using the modified ellipsoid formula: V = (L x W^2) / 2.
5. Randomization & Treatment Initiation: When tumors reach the predetermined baseline volume (typically 100-150 mm^3), animals are randomized into treatment and control cohorts stratified by tumor size. Test articles are administered according to the predefined dosing regimen (IV, IP, PO, or intravesical as applicable).
6. In-Life Monitoring & Data Collection: Throughout the treatment phase, body weight, tumor dimensions, and clinical signs are recorded systematically. Blood samples may be collected at defined intervals for pharmacokinetic analysis. Tumor growth inhibition (TGI) is calculated relative to vehicle controls.
7. Endpoint Analysis & Tissue Collection: At study termination, tumors are excised, weighed, and processed for downstream analyses including histopathology (H&E), immunohistochemistry (IHC), Western blotting, RNA sequencing, or flow cytometry as specified in the study protocol.
8. Data Compilation & Reporting: All raw data, statistical analyses, and representative images are compiled into a comprehensive study report with statistical significance testing, ensuring your data package is audit-ready and suitable for regulatory submissions or peer-reviewed publication.

Figure 2. 5637 xenograft model construction workflow.

Case Study-5637 Xenograft Model Development

Alfa Cytology has successfully established and validated the 5637 xenograft model across multiple independent studies, consistently achieving robust tumor take rates and predictable growth kinetics suitable for preclinical drug evaluation. Our internal datasets demonstrate reliable subcutaneous tumor formation with median latency periods and growth rates that align with published literature, enabling precise power calculations for study design. Detailed efficacy data, including tumor growth inhibition curves, survival analyses, and biomarker modulation profiles, are available upon request under confidentiality agreements. For access to comprehensive case study materials and customized data packages, please contact our scientific team to discuss your specific program requirements.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your 5637 bladder cancer xenograft studies means accessing a CRO committed to scientific rigor, operational transparency, and client-centric flexibility. Our integrated platform combines experienced oncology study directors, validated animal facilities, and cutting-edge analytical capabilities to deliver data you can trust.

• Authenticated, low-passage 5637 cell banks with comprehensive pathogen screening and STR verification ensure model fidelity from study initiation.
• Standardized, GLP-aligned xenograft workflows with rigorous IACUC oversight and veterinary care guarantee ethical compliance and data reproducibility.
• Real-time tumor monitoring and digital data capture systems provide transparent study progress tracking and rapid decision-making support.
• Flexible study designs accommodate single-agent efficacy, combination therapy, dose-ranging, and mechanistic biomarker endpoints tailored to your development stage.
• Comprehensive endpoint analysis including histopathology, IHC, molecular profiling, and PK-PD integration delivers a complete preclinical data package.
• Dedicated project management and scientific consultation ensure seamless communication, timeline adherence, and regulatory-ready reporting throughout your engagement.

Contact Us

Ready to advance your bladder cancer therapeutic program with a validated 5637 xenograft model? Reach out to Alfa Cytology today to discuss your study objectives, receive a customized proposal, and partner with a CRO dedicated to turning your preclinical vision into actionable, high-quality data. Our scientific team is standing by to support your research from initial consultation through final report delivery---contact us now and take the next step toward clinical success. Please reach out to us today via our inquiry form or email to learn more about our 5637 Xenograft Model services.

For research use only. Not intended for any clinical use.